Department of Pediatrics, Pediatric Pulmonology, University Hospital of Leuven, Leuven, Belgium.
J Cyst Fibros. 2013 Jan;12(1):29-34. doi: 10.1016/j.jcf.2012.06.001. Epub 2012 Jul 2.
In patients with cystic fibrosis (CF), treatment of new Pseudomonas aeruginosa (Pa) infection postpones the occurrence of chronic infection, but the best eradication regimen is unknown .
Compare 2 Pa eradication regimens in children with new Pa infection.
Children with CF (0-18 years) and a new isolation of Pa from sputum, cough swab or BAL were randomized to treatment with tobramycin inhalation solution for 28 days (TIS) or inhaled sodiumcolistimethate (2×2millU/day) plus oral ciprofloxacin (30 mg/kg/day) for 3 months (CC). Airway cultures were taken for 6 consecutive months, then every 3 months. The primary outcome was Pa eradication at the end of treatment. Secondary outcome parameters were: time to Pa relapse from end of treatment, total and Pa specific IgG, FEV(1), BMI and Pa status at 2year follow-up.
58 patients with new Pa isolation were randomized. Their median age was 9 years (IQR 4.7-13.1) and their median FEV(1) 98% predicted (IQR 87-107). Eighteen treatments concerned the first Pa isolation 'ever' (TIS: 8; CC: 10). For the remaining, median time since previous Pa was 19 months (IQR 9-41). Eradication at end of treatment was similar for both treatments: 26/29 CC and 23/29 in TOBI treated patients (p=0.47). Median time to recurrence of Pa was 9 months (95% CI 0.0-19.0) for CC and 5 months (95% CI 1.7-8.3) for TIS (p=0.608). After 1 year, the 2 groups did not differ in change in total and Pa specific IgG, FEV(1) and BMI. After 2 years, 10% of patients had chronic Pa infection.
In children with CF and new Pa infection, inhalation of TIS (28 days) or CC (3 months) resulted in similar eradication success at the end of treatment (80 and 90% respectively) and similar clinical evolution during the first 2 years of follow-up.
比较两种新分离铜绿假单胞菌(Pa)感染患儿的铜绿假单胞菌清除方案。
将 0-18 岁 CF 患儿中痰液、咳嗽拭子或 BAL 中分离出的新 Pa 进行随机分组,接受为期 28 天的妥布霉素吸入溶液(TIS)或吸入用黏菌素钠(2×2 万单位/天)+口服环丙沙星(30mg/kg/天)治疗 3 个月(CC)。连续 6 个月采集气道培养物,然后每 3 个月采集一次。主要结局为治疗结束时 Pa 的清除率。次要结局参数包括:从治疗结束到 Pa 复发的时间、总 IgG 和 Pa 特异性 IgG、FEV(1)、BMI 和 2 年随访时 Pa 状态。
58 例新分离 Pa 的患儿被随机分组。他们的中位年龄为 9 岁(四分位距 4.7-13.1),中位 FEV(1)为预计值的 98%(87-107)。18 例治疗方案涉及首次 Pa 分离“ever”(TIS:8;CC:10)。对于其余患儿,从上次 Pa 到本次的中位时间为 19 个月(四分位距 9-41)。治疗结束时的清除率在两组之间相似:CC 组 26/29 例,TIS 组 23/29 例(p=0.47)。CC 组 Pa 复发的中位时间为 9 个月(95%CI 0.0-19.0),TIS 组为 5 个月(95%CI 1.7-8.3)(p=0.608)。1 年后,两组在总 IgG 和 Pa 特异性 IgG、FEV(1)和 BMI 的变化上无差异。2 年后,10%的患儿患有慢性 Pa 感染。
在 CF 患儿中,新分离 Pa 感染患儿接受 TIS(28 天)或 CC(3 个月)治疗,在治疗结束时(分别为 80%和 90%)清除率相似,在随访的前 2 年中临床转归相似。